https://www.selleckchem.com/pr....oducts/afuresertib-g
After two decades teetering at the intersection of laboratory tool and therapeutic reality, with two siRNA drugs now clinically approved, this modality has finally come into fruition. Consistent with other emerging modalities, initial proof-of-concept efforts concentrated on coupling pharmacologic efficacy with desirable safety profiles. Consequently, thorough investigations of siRNA absorption, distribution, metabolism and excretion (ADME) properties are lacking. Advancing ADME knowledge will aid establishment of in vitr
Curtir
Comentario
Compartilhar
